Alzheimer’s Therapeutics Market
                     Alzheimer’s Therapeutics 
Market to Reach USD 12.43 
Billion By 2026
www.reportsanddata.com
Market 
RSisinug imncidemnce aof irnvyestment in biomarkers for drug development is the major factor influencing market 
growth.
Market Size – USD 6.8 billion in 2018, Market Growth - CAGR of 9.23%, Market Trends –Rise in advanced 
diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics 
technologies.
The Alzheimer’s Therapeutics Market is expected to reach USD 12.43 Billion by 2026, according to a new report 
by Reports and Data. This can be mainly associated with the growing pipeline drug development, investment in 
biomarkers for drug development which are expected to further accelerate the market growth globally. Based on 
statistics, increase in advanced diagnostics for early detection, along with more specific drug development, and 
emerging innovative diagnostics technologies are also some of the factors that are also helping to grow the size of 
the global market.
www.reportsanddata.com
Market 
ASlzheimer's disease (AD) is the most usual cause of dementia worldwide. The study of tuhism dismeasea isr myultifactorial, and pathophysiology is also complicated. According 
to several types of research, an exponential rise in the number of cases of AD, 
highlighting the need for developing an effective treatment. AD also imposes a 
tremendous emotional and financial trouble to the patient's family and society. The 
disease has been studied for more than a century, but memantine and 
acetylcholinesterase inhibitors are the only drugs currently recommended for its 
management. These drugs provide significant improvement alone but do less to 
change the disease process. The significant penetration into the molecular and 
cellular pathomechanism in AD over the previous few decades has given us 
considerable progress in the understanding of the disease. Several novel strategies 
that seek to revise the disease process have been developed. The notable 
developments in this direction are the tau-based and amyloid therapeutics, which 
could hold the key to treatment of AD shortly.
Further key findings from the report suggest-
• Cholinesterase inhibitors therapeutics accounts for the largest share of 38.85% in 2018. It can 
also improve neuropsychiatric symptoms, such as depression or agitation.
• Generally prescribed cholinesterase inhibitors are galantamine (Razadyne), donepezil (Aricept), 
and rivastigmine (Exelon).
Avail the inside scoop of the Sample report @ 
https://www.reportsanddata.com/sample-enquiry-form/1364 www.reportsanddata.com
Market 
Summary
Companies considered and profiled in this market study
Eli Lilly and Company, Daiichi Sankyo Hoffmann-La Roche Ltd, Pfizer, Inc., Eisai Co., Ltd., Novartis AG, H. Lundbeck 
A/S, TauRx Therapeutics Ltd, Forest Laboratories, Inc., AC Immun, Johnson & Johnson, TauRx Pharmaceuticals Ltd, 
VTV Therapeutics
For the purpose of this study, Reports and Data have segmented the global Alzheimer’s Therapeutics Market on the 
basis of Therapeutics, End-User, Diagnostics Type and Region:
Therapeutics  Outlook (Revenue, USD Million; 2016-2026)
• Cholinesterase inhibitors
• Pipeline Drugs
• NMDA receptor antagonist
End User Outlook (Revenue, USD Million; 2016-2026)
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce
www.reportsanddata.com
Market 
Summary
Diagnostics Type  Outlook (Revenue, USD Million; 2016-2026)
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Lumbar puncture test
• Electroencephalography (EEG)
• Others
Regional Outlook (Revenue in USD Million; 2016–2026)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)
Download Summary: https://www.reportsanddata.com/download-summary-form/1364
www.reportsanddata.com
About Us
Reports and Data is a market research and 
consulting company that provides syndicated research 
reports, customized research reports, and consulting 
services. Our solutions purely focus on your purpose to 
locate, target and analyze consumer behavior shifts Contact US
across demographics, across industries and help client’s 
make a smarter business decision. 
John Watson
We offer market intelligence studies ensuring relevant Head of Business Development
and fact-based research across a multiple industries Reports And Data | Web: 
including Healthcare, Technology, Chemicals, Power, and www.reportsanddata.com
Energy. We consistently update our research offerings Direct Line: +1-212-710-1370
to ensure our clients are aware about the latest trends E-mail: [email protected]
existent in the market. Reports and Data has a strong 
base of experienced analysts from varied areas of 
expertise.
www.reportsanddata.com